文献速递消化系统肿瘤

循环肿瘤DNA作为局限性胰腺癌术后辅助化疗获益的潜在标志物

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

这项前瞻性生物标志物试验评估循环肿瘤DNA(ctDNA)分析指导辅助治疗决策的可行性与潜在临床效用。112例术前知情同意的可切除胰腺腺癌患者中81例(72%)接受切除,术后可检测ctDNA者复发率100%,术前和/或术后ctDNA检测与无复发生存期和总生存期较差相关。

要点

  • 可切除胰腺癌中KRAS突变在91%(38/42)的肿瘤样本中检出。
  • 术前ctDNA检出与较差的无复发生存期(HR 4.1;P=0.002)和总生存期(HR 4.1;P=0.015)相关。
  • 术后可检测ctDNA者复发率100%(13/13),包括7例接受吉西他滨为基础辅助化疗者。

核心结论

  • 局限性胰腺癌的ctDNA研究具有挑战性,相当数量患者无法接受切除、无足够肿瘤组织分析或未完成方案规定的样本采集。
  • 术前和/或术后ctDNA分析是有前景的预后标志物。
  • ctDNA指导治疗的研究是合理的,包括对术后可检测ctDNA且尽管接受吉西他滨为基础辅助治疗仍看似极高复发风险的患者采用治疗强化策略。

研究设计与样本

  • 前瞻性生物标志物试验,入组经多学科团队评估为可切除胰腺腺癌的患者。
  • 采集术前和术后样本进行ctDNA分析,使用基于PCR的SafeSeqS方法检测原发胰腺肿瘤KRAS密码子12、13和61突变并检测ctDNA。
  • 112例术前知情同意,81例(72%)接受切除。

主要发现

  • KRAS突变在91%(38/42)的可用肿瘤样本中检出。
  • 在可用血浆样本(N=42)中,术前KRAS突变ctDNA检出率为62%(23/37),术后为37%(13/35)。
  • 中位随访38.4个月,术前ctDNA检出与较差的无复发生存期(HR 4.1;P=0.002)和总生存期(HR 4.1;P=0.015)相关。
  • 根治性切除后检测到ctDNA与较差的无复发生存期(HR 5.4;P<0.0001)和总生存期(HR 4.0;P=0.003)相关。
  • 术后可检测ctDNA的患者中复发13/13(100%),包括7例接受吉西他滨为基础辅助化疗者。

临床怎么用

  • 患者管理按标准治疗进行,对ctDNA数据设盲。

局限性

  • ctDNA研究在局限性胰腺癌中具有挑战性,相当数量患者无法接受切除、无足够肿瘤组织分析或未完成方案规定的样本采集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to inform adjuvant therapy decision making. MATERIALS AND METHODS: Patients considered by the multidisciplinary team to have resectable pancreatic adenocarcinoma were enrolled. Pre- and post-operative samples for ctDNA analysis were collected. PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA. Results of ctDNA analysis were correlated with CA19-9, recurrence-free and overall survival (OS). Patient management was per standard of care, blinded to ctDNA data. RESULTS: Of 112 patients consented pre-operatively, 81 (72%) underwent resection. KRAS mutations were identified in 91% (38/42) of available tumor samples. Of available plasma samples (N = 42), KRAS mutated ctDNA was detected in 62% (23/37) pre-operative and 37% (13/35) post-operative cases. At a median follow-up of 38.4 months, ctDNA detection in the pre-operative setting was associated with inferior recurrence-free survival (RFS) [hazard ratio (HR) 4.1; P = 0.002)] and OS (HR 4.1; P = 0.015). Detectable ctDNA following curative intent resection was associated with inferior RFS (HR 5.4; P < 0.0001) and OS (HR 4.0; P = 0.003). Recurrence occurred in 13/13 (100%) patients with detectable ctDNA post-operatively, including in seven that received gemcitabine-based adjuvant chemotherapy. CONCLUSION: ctDNA studies in localized pancreatic cancer are challenging, with a substantial number of patients not able to undergo resection, not having sufficient tumor tissue for analysis or not completing per protocol sample collection. ctDNA analysis, pre- and/or post-surgery, is a promising prognostic marker. Studies of ctDNA guided therapy are justified, including of treatment intensification strategies for patients with detectable ctDNA post-operatively who appear at very high risk of recurrence despite gemcitabine-based adjuvant therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019. PMID: 31250894. doi:10.1093/annonc/mdz200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。